Literature DB >> 25833661

Impact of 2004 ISUP/WHO classification on bladder cancer grading.

Soum D Lokeshwar1, Roberto Ruiz-Cordero2, Marie C Hupe3, Merce Jorda4, Mark S Soloway5.   

Abstract

PURPOSE: To determine whether implementation of the 2004 WHO/ISUP bladder cancer (BCa) grading system caused a grade migration, i.e., more tumors being graded as high grade (HG).
METHODS: Data on 1040 BCa cases from 668 patients treated at our institution between 2000 and 2013 and reviewed by six pathologists were evaluated: low grade (LG): 249; HG: 791; Ta: 389; T1: 214; CIS: 95; ≥T2: 342. Differences in LG or HG cases (expressed as %BCa cases/year) were analyzed by Mann-Whitney test. Correlation between the year of diagnosis and clinical/pathological parameters was evaluated by logistic regression analyses.
RESULTS: During the study period, BCa cases diagnosed as LG significantly decreased with a corresponding increase in HG cases. Nonlinear regression analysis indicated that ~2008 was the crossover point for grade migration; %LG: 31.8 ± 4.8 (2000-2007); 14.1 ± 7.0 (2008-2013); %HG: 68.2 ± 4.8 (2000-2007); 85.9 ± 6.9 (2008-2013), P = 0.004. The grade migration was confined to Ta cases with %LG Ta cases diagnosed decreasing by 3.6-fold from 2000-2007 to 2008-2013 (P = 0.004). Univariate and multivariate analyses confirmed the grade migration following the adoption of the 2004 system (P < 0.0001). Kaplan-Meier curves showed no significant differences between the two time intervals in terms of disease progression (P > 0.05).
CONCLUSIONS: Implementation of the 2004 WHO/ISUP system caused a significant increase in pathologists grading Ta cases as HG; however, this increase did not seem to correlate with disease progression. Since LG and HG Ta tumors are treated differently, grade migration may impact the clinical management of BCa patients.

Entities:  

Keywords:  1998 WHO/ISUP grading; 2004 WHO grading; Bladder cancer; Progression

Mesh:

Year:  2015        PMID: 25833661     DOI: 10.1007/s00345-015-1548-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  29 in total

1.  The "WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms": continued discussion.

Authors:  V E Reuter; J I Epstein; M B Amin; F K Mostofi
Journal:  Hum Pathol       Date:  1999-07       Impact factor: 3.466

2.  Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder.

Authors:  Chin-Chen Pan; Yen-Hwa Chang; Kuang-Kuo Chen; Hui-Jung Yu; Chih-Hao Sun; Donald M T Ho
Journal:  J Clin Pathol       Date:  2010-10       Impact factor: 3.411

3.  The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading.

Authors:  Bas W G van Rhijn; Geert J L H van Leenders; Bert C M Ooms; Wim J Kirkels; Alexandre R Zlotta; Egbert R Boevé; Adriaan C Jöbsis; Theo H van der Kwast
Journal:  Eur Urol       Date:  2009-09-11       Impact factor: 20.096

Review 4.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

5.  Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years.

Authors:  A Bergkvist; A Ljungqvist; G Moberger
Journal:  Acta Chir Scand       Date:  1965-10

Review 6.  Current management of non-muscle-invasive bladder cancer.

Authors:  O Rodriguez Faba; J M Gaya; J M López; M Capell; A E De Gracia-Nieto; E Gómez Correa; A Breda; J Palou
Journal:  Minerva Med       Date:  2013-06       Impact factor: 4.806

Review 7.  The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer.

Authors:  Wolfgang Otto; Stefan Denzinger; Hans-Martin Fritsche; Maximilian Burger; Wolf F Wieland; Ferdinand Hofstädter; Arndt Hartmann; Simone Bertz
Journal:  BJU Int       Date:  2010-08-12       Impact factor: 5.588

Review 8.  Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.

Authors:  Donna E Hansel; Jeremy S Miller; Michael S Cookson; Sam S Chang
Journal:  Urology       Date:  2013-03-19       Impact factor: 2.649

Review 9.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

Authors:  Maximilian Burger; Willem Oosterlinck; Badrinath Konety; Sam Chang; Sigurdur Gudjonsson; Raj Pruthi; Mark Soloway; Eduardo Solsona; Paul Sved; Marko Babjuk; Maurizio A Brausi; Christopher Cheng; Eva Comperat; Colin Dinney; Wolfgang Otto; Jay Shah; Joachim Thürof; J Alfred Witjes
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

10.  Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up.

Authors:  Hui Yin; Anthony S Y Leong
Journal:  Am J Clin Pathol       Date:  2004-05       Impact factor: 2.493

View more
  9 in total

1.  SIU-ICUD on bladder cancer: pathology.

Authors:  Eva Compérat; Marek Babjuk; Ferran Algaba; Mahul Amin; Fadi Brimo; David Grignon; Donna Hansel; Ondra Hes; Bernard Malavaud; Victor Reuter; Theo van der Kwast
Journal:  World J Urol       Date:  2018-09-14       Impact factor: 4.226

2.  Radiomics assessment of bladder cancer grade using texture features from diffusion-weighted imaging.

Authors:  Xi Zhang; Xiaopan Xu; Qiang Tian; Baojuan Li; Yuxia Wu; Zengyue Yang; Zhengrong Liang; Yang Liu; Guangbin Cui; Hongbing Lu
Journal:  J Magn Reson Imaging       Date:  2017-02-15       Impact factor: 4.813

3.  A Festschrift in Honor of Edward M. Messing, MD, FACS.

Authors:  Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump
Journal:  Bladder Cancer       Date:  2018-10-03

Review 4.  Bladder cancer: Active surveillance for low-grade Ta bladder tumours.

Authors:  Mark S Soloway
Journal:  Nat Rev Urol       Date:  2016-02-16       Impact factor: 14.432

Review 5.  Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.

Authors:  Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

6.  CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer.

Authors:  Xiao-Guang Zhang; Tong Zhang; Chang-Ying Li; Ming-Hao Zhang; Fang-Min Chen
Journal:  Cancer Med       Date:  2018-07-18       Impact factor: 4.452

7.  Presence and predominance of histological grade 3 define cT1HG bladder cancer prognostic groups.

Authors:  Leonardo Oliveira Reis; Luciana S B Dal Col; Diego M Capibaribe; Gustavo B de Mendonça; Fernandes Denardi; Athanase Billis
Journal:  Investig Clin Urol       Date:  2022-01

8.  Is there a role for second transurethral resection in pTa high-grade urothelial bladder cancer?

Authors:  Anuj Deep Dangi; Ramani Manoj Kumar; Thomas Alex Kodiatte; Mahasampth Gowri; Santosh Kumar; Antony Devasia; Nitin Kekre
Journal:  Cent European J Urol       Date:  2018-06-12

9.  A retrospective analysis of the correlation between AXL expression and clinical outcomes of patients with urothelial bladder carcinoma.

Authors:  Lining Wang; Kangkang Liu; Jianpeng Yu; Erlin Sun
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.